Nimbus Therapeutics, Inc.
https://www.nimbustx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nimbus Therapeutics, Inc.
2023-2024 Global Biopharma R&D Productivity And Growth Ranking
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
Potential Competitor To BMS’s Sotyktu Bites The Dust
Already abandoned for psoriasis and psoriatic arthritis, the failure of Ventyx's TYK2 inhibitor for Crohn’s disease signals the end of the project, leaving Takeda and Alumis as BMS's principal rivals in the field.
Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
Takeda Tightens Belt As It Anticipates Difficult 2024, With Growth Returning After
The drug maker has its eye on six Phase III or Phase III-ready programs that it hopes will return the company to growth. It also highlighted investments in AI and digital technology.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Other Names / Subsidiaries
-
- Nimbus Discovery LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice